Oramed Pharmaceuticals Inc.
ORMP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001176309
No open-market purchases or sales by Oramed Pharmaceuticals Inc. insiders were filed in the last 90 days; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Oramed Pharmaceuticals Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 57 | 1 | 64 | +8 |
| Shares | 13.1M | 1.90M | 13.2M | +2.08M (+18.7%) |
| Value | $37.2M | $5.42M | $45.0M | +$13.2M (+41.6%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Oramed Pharmaceuticals Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mercer Global Advisors Inc | 1,910,540 | $6.50M | 0.01% |
| Ritholtz Wealth Management | 155,479 | $528.6K | 0.01% |
| O'Shaughnessy Asset Management, LLC | 116,363 | $395.6K | 0.00% |
| Hillsdale Investment Management Inc. | 97,300 | $330.8K | 0.01% |
| Hudson Bay Capital Management LP | 51,670 | $175.7K | 0.00% |
| Bailard, Inc. | 32,478 | $110.4K | 0.00% |
| Qube Research & Technologies Ltd | 23,504 | $79.9K | 0.00% |
| Catalyst Funds Management Pty Ltd | 23,500 | $79.9K | 0.01% |
| Omers Administration Corp | 18,400 | $62.6K | 0.00% |
| Millennium Management LLC | 16,018 | $54.5K | 0.00% |
| Kathmere Capital Management, LLC | 15,071 | $51.2K | 0.00% |
| Acadian Asset Management LLC | 15,066 | $50.0K | 0.00% |
| Axq Capital, LP | 11,326 | $38.5K | 0.00% |
| Citigroup Inc | 8,989 | $30.6K | 0.00% |
| Royal Bank of Canada | 174 | $1.00K | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | $7 | 0.00% |
Sold out (8)
Institutions that held Oramed Pharmaceuticals Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Squarepoint Ops LLC | 58,272 | $166.1K |
| RBF Capital, LLC | 42,947 | $122.4K |
| Quadrature Capital Ltd | 41,734 | $118.9K |
| Two Sigma Securities, LLC | 23,143 | $66.0K |
| LPL Financial LLC | 13,185 | $37.6K |
| Mariner, LLC | 11,021 | $31.4K |
| Caitlin John, LLC | 1,000 | $2.85K |
| Tower Research Capital LLC (TRC) | 693 | $1.98K |
Not filed for Q1 2026 yet (1)
Institutions that held Oramed Pharmaceuticals Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| SB Capital Management Inc | 1,900,000 | $5.42M |